Acute bone damage through liver-bone axis induced by thioacetamide in rats

Xiaoli Jin, Yang Li, Jianghua Li, Linyan Cheng, Yetao Yao, Hao Shen, Bili Wang, Jun Ren, Hang Ying and Jian Xu

Abstract

Background: Thioacetamide (TAA) is used in various fields, such as synthetic drugs, organic chemical synthesis, and materials chemistry. TAA is mainly used to establish animal liver injury models and other organ damage models to explore their mechanisms for helping patients with liver disease. Liver damage can lead to abnormal expression of some enzymes in the serum, so we detected the appropriate enzyme levels in the serum of SD rats to verify the damage of TAA to the liver. More importantly, TAA caused bone damage is barely understood. Therefore, our research aims to establish a rat model reflecting the acute bone damage injury caused by TAA.

Methods: The SD rats were intraperitoneally injected with normal saline (0.9%) or TAA (200 mg/kg, 400 mg/kg) for 1 month (once the other day). After the last intraperitoneal injection, serum samples from rats were used for biochemical tests. Masson staining is used to detect liver damage, and micro-CT is used to detect the changes in bone. Moreover, the three-point bending experiment was used to detect the force range of the hind limbs of SD rats.

Results: Compared with the control group, after the intraperitoneal injection of TAA, the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), uric acid (UA), total bile acid (TBA), alkaline phosphatase (ALP), carbamide (UREA) and creatinine (CREA) rose sharply, while the levels of serum content of total protein (TP), lactate dehydrogenase (LDH), calcium (Ca) and phosphorus (P) were severely reduced. After TAA administration, collagen fibers were deposited and liver fibrosis was obvious. Micro-CT results showed that the bone surface, tissue surface, bone volume, and tissue volume of rats with an intraperitoneal injection of TAA were significantly reduced. In addition, the bones of rats with an intraperitoneal injection of TAA can resist less pressure and are prone to fractures.

Conclusions: TAA can cause liver damage in SD rats, which is explained by the changes in serum biochemical indicators and the deposition of liver collagen. More importantly, TAA can reduce bone mineral density and increase the separation of bone trabeculae in SD rats, and finally lead to bone injury. This suggests that TAA may become an ideal model to investigate abnormal bone metabolism after liver injury.

Keywords: Bone damage, Hepatic fibrosis, Thioacetamide, Rat model

Background

Thioacetamide (TAA) is a widely used commercial chemical, and it has been used as an organic solvent in textile and paper industries [1]. In 1948, Fitzhugh [2] found liver tumors in rats fed with TAA. The study exhibited a number of thiono-sulfur containing compounds, including TAA having toxic properties. These effects included bone marrow depression, liver damage, and lung damage [3].
In recent years, some researchers have paid attention to the reason TAA causes liver damage; TAA mediated by microsomal CYP2E1 to TAA-S or S-dioxide initiates cellular necrosis [4, 5]. Karantonis [6] suggested that reducing the levels of reactive oxygen species may improve liver damage, and the platelet-activating factor participated in the liver fibrotic process. Other researchers [7] also explored how to inhibit TAA toxicity in the liver, and how hepatic irradiation preconditioning enhances the effect of bone marrow-derived mesenchymal stem cells' effect on TAA-induced liver fibrosis in rats. A study demonstrates that a small-molecule inhibitor of connexin 32 can protect against liver failure and death in wild-type mice when co-administered with TAA [8], as well as miR-34a-5p, a microRNA that was the most suitable and sensitive biomarker for TAA-treated hepatic carcinoma [9]. In addition, metabolic bone disease is common among patients with chronic liver disease [10, 11], associated with alterations in receptor activator of nuclear factor-κB ligand and osteoprotegerin serum levels [12]. When the function of the liver is abnormal, such as in chronic hepatitis C, liver fibrosis, liver cirrhosis and even liver cancer, the bone will also be damaged [13-15]. It is evident that TAA causes liver damage, although, TAA causing bone damage is barely understood. Bone damage associated with TAA toxicity was discovered as early as 1984. Lassila V [16] proposed that TAA-induced liver injury accompanied changes in serum proteins and alveolar bone, mainly around teeth, during occlusal stress and trauma, while significantly reducing the activity of osteoblasts and bone mass, and reducing formation of new bone. In 1996, Nakano [17] also proposed using carbon tetrachloride (CCL₄) and TAA to establish liver cirrhosis models, as TAA and CCL₄-induced liver cirrhosis can cause osteodystrophy, which is mainly responsible for bone volume reduction. The skeletal system includes bone, cartilages, ligaments, connective tissues, and the femur, a weight-bearing bone that transfers weight from the hip joint to the knee joint [18]. Our laboratory hopes to establish an animal model of osteoporosis by intraperitoneal injection of thioacetamide, and explore the mechanism of TAA causing bone damage.

**Methods**

**Chemical**

TAA was obtained from Sangon Biotech Co., Ltd. (Shanghai, China), and >98% purity was analyzed. It was dissolved in normal saline.

**Animals**

All experiments in this study were conducted in accordance with the animal experiment guidelines of the Zhejiang Chinese Medical University Laboratory Animal Research Center (Approval No: IACUC-20181029-11). Sprague-Dawley rats (18 Male; 200–250g) were obtained from Shanghai BK company and bred in the Animal Experimental Center of the Zhejiang Institute of Traditional Chinese Medicine in Hangzhou. The laboratory diet of the rats was based on a standard AIN-93 laboratory diet (Xietong Biotechnology, Nanjing, China) and kept in an ambient room with the following conditions: temperature (20±2°C), humidity 60%~65% and light (12h light-dark cycle). They were acclimatized for 4 days before the study started. 18 rats were randomly divided into three groups (n=6/group), (1) normal control, in which the rats received normal saline, the same injection volume with the heaviest in the high dose group, (2) low dose group, in which treated with TAA of 200mg/Kg, (3) high dose group, in which treated with TAA of 400mg/Kg. The experimental animals were injected intraperitoneally with TAA or normal saline every other day for 1 month, 15 times in total. Before rats were intraperitoneal injection, we had weighted every rat. Animal experiments were conducted according to the Guidelines for Animal Experimentation at our animal center. After fasting for 24hours, all rats were anesthetized by intraperitoneal injection of sodium pentobarbital (45mg / kg), and the retroorbital blood was collected for biochemical analysis. Then the abdominal cavity was then opened from the midline of the abdomen. Liver and limb bones were taken for follow-up experiments. The rats eventually died due to excessive blood loss in the whole process, and the rats did not feel severe pain.

**Serum biochemical analysis**

Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total protein (TP), total bile acid (TBA) (AST·ALT·ALP·LDH·TP and TBA are indicators of liver function), calcium (Ca), phosphorus (P) (Ca and P are indicators of bone function), carbamide (UREA) and creatinine (CREA) uric acid (UA) (UREA·CREA and UA are indicators of renal function) were analyzed via Hitachi automatic analyzer 3100 (in the Zhejiang Chinese Medical University Laboratory Animal Research C enter) and present data.

**Histopathological examination**

Immediately after sacrifice, the liver tissues were removed and instantly fixed in 10% neutral buffered formalin for 24h. After fixation, the tissue samples were dehydrated with gradient ethanol from a low to a high concentration, dewaxed with xylene, soaked in wax, and then embedded to make tissue wax blocks by the biological tissue embedding machine (KeDee, China), which were all processed by the conventional paraffin embedding technique. Paraffin-embedded liver sections were cut to 4μm thickness by the Paraffin
slicer (Thermo, the USA), the wax strips were placed on the water surface of the biological tissue spread baking machine (KeDee, China), and scooped up with glass slides after leveled, which were baked through Masson’s trichrome (MT) stain and examined under a light microscope to detect collagen deposition. Masson staining showed that collagen fibers were blue and muscle fibers were red, indicating the number of threads in the tissue.

Micro-computed tomography (μCT) analysis
The bone structure of rat left posterior femurs was determined by μCT scans (Bruker, Kontich, Belgium, Institute of Orthopaedic and Traumatology of Zhejiang Province, Hangzhou, Zhejiang, China), to assess the cortical bone and the trabecular bone, which was scanned with standard parameters (70 kV, 357 μA, power 25 W, exp. osure time 270 ms, resolution 18 μm). The intact femur metaphyseal regions were scanned by micro-CT and the range of interest (ROI) was about 2 mm from the femoral growth plate. Total surface area (TS), bone surface area (BS), bone volume (BV), total volume (TV), bone mineral density (BMD), structural model index (SMI), degree of anisotropy (DA), trabecular number (Tb.N), trabecular bone pattern factor (TBPF), trabecular separation-spacing (Tb.Sp), trabecular thickness (Tb.Th) of the femoral were determined.

Three-point bending experiment
The three-point bending experiment was carried out at the Institute of Orthopedics and Traumatology of Zhejiang Chinese Medical University. The maximum load of rat femur was measured by the AGS-I series precision electronic universal material experiment machine. The femur was loaded onto the 17 mm span in an anterior-posterior position, and a load was applied to the midshaft of the femur, on the anterior surface, at a uniform speed of 10 mm/min until the bone specimen was broken. The load-deformation curve was plotted, and the analysis data was recorded.

Statistical analysis
All experimental data are expressed as the means ± SD. Statistically significant differences between groups were assessed
by a one-way analysis of variance (Anova) followed by Tukey’s post hoc test. All data were analyzed using the SPSS statistical package version 22.0 for Windows (IBM, Armonk, NY, USA). P < 0.05 indicated a statistically significant difference.

Results
TAA inhibited the growth of SD rats
After intraperitoneal injection of the drug, SD rats were anesthetized and sacrificed. It can be seen that TAA can inhibit the growth of SD rats (Fig.1). As the concentration of TAA increased, the growth and development inhibition of SD rats were more obvious.

TAA induced liver injury
After the injection of normal saline and different doses of TAA, the relevant biochemical indicators changed significantly. The levels of serum AST, ALT, and UA were increased dramatically in the high dose group, while there was no obvious change in the low dose group. Figures 2D and E showed that after intraperitoneal injection of TAA, the serum TP and LDH of SD rats decreased, while TBA
and ALP increased. It showed that TAA could cause liver damage. Compared with the normal control group, the levels of serum Ca and P decreased to varying degrees after intraperitoneal injection of TAA. However, the high dose group significantly increased UREA and CREA levels. This suggested that TAA may cause bone and kidney damage.

Figure 3 showed Masson staining of the liver-pathological sections of the control group and different doses of the TAA group. Masson staining showed that hepatocytes in the normal control group were closely connected without fibrous dysplasia. In the groups of intraperitoneal injection of TAA, there were many abnormal hyperplasias of reticular fibers in the portal area, and the fiber spacing widened, with obvious collagen deposition. This showed that TAA could induce liver fibrosis in SD rats.

**TAA induced bone injury in SD rats**

The three-dimensional structure of the femur was analyzed by NRecon software (Fig. 4) to detect the possibility of bone injury in SD rats which was related to TAA treatment. At the same time, we obtained a planar Micro-CT image of the distal end (Fig. 5). It can clearly be concluded that from the normal control group to the TAA-treated group, the bone volume dropped dramatically, the thickness of trabecular bone decreased, and the separation of trabecular bone increased. At last, the three-point bending experiment was used to test the femoral force range.
of the hind limbs of SD rats (Fig. 6). The results showed that with the increase in TAA concentration, the force range of the femur decreased gradually.

**Discussion**

In 1948, researchers suggested that TAA has hepatoxicity, leading to liver fibrosis, and even producing liver tumors in a certain drug concentration and within a certain time. At the same time, the researchers could not find that TAA had an effect on other organs, and suggested that the extent to which certain organs were affected may not be discovered, and further research is needed [2]. Then, TAA has been shown to cause cholangiocarcinoma [19]. Some scholars have also found that TAA not only damages the liver of animals, but also affects the kidneys, brain, spleen, and bone of animals [16, 20–22]. When TAA treated the liver of the animal model the enzyme metabolism of the liver, protein, adipose, amino acid, and the messenger RNA was changed to varying degrees as compared to the normal group [9, 23–26]. However, most scholars are concerned about the role of TAA in the liver and its mechanism. A few scholars are concerned about the bone damage caused by TAA.
Our data underline that rats with severe liver diseases result in osteopenia, especially in weight-bearing bones. Changes in body weight levels were observed in the three groups, and significant weight loss was observed in 200 mg/kg TAA and 400 mg/kg TAA groups, indicating that intraperitoneal injection of TAA could affect the growth of rats. Additionally, the increased concentration of AST and ALT represented severe liver injury, and the increased concentration of UA, UREA, CREA, and TBA represented severe kidney injury, which correlates with other research [27, 28]. We also found a decreased concentration of TP and an increased concentration of ALP, which indicated liver disease [29]. The levels of rat serum ALT, AST, and ALP exposed to TAA were significantly increased, indicating that the liver cell membrane was impaired and their release into the bloodstream was increased after TAA administration. Our data showed serum calcium concentration of 200 mg/Kg TAA and 400 mg/Kg TAA group was decreased compared with the control group; the reason for decreased serum calcium is associated with the progression of cell injury since alterations in cell signaling play a determinant role in the toxicological processes [30]. Serum phosphorus is primarily in the form of inorganic phosphate, which is maintained within the physiological range by the regulation of bone formation, dietary absorption, renal excretion, and equilibration with intracellular stores. Long-standing phosphorus deficiency will increase the risk of osteomalacia [31]. The concentration of serum phosphorus in our data was decreased compared to the TAA-treated group with a control group, which is as expected in other literature. LDH is an insensitive index of all types of hepatic necrosis except hypoxic [32]; the level of LDH was not increased compared to the TAA-treated group with a control group in our studies. In our rat model, TAA-treated animals developed severe liver fibrosis as demonstrated by Masson staining, which correlates with other studies [33]. Masson staining showed that the deposition of liver collagen fibers increased after TAA administration, and liver fibrosis was obvious.

In conclusion, we successfully established a rat model of liver injury caused by TAA. Neal [3] has reported that thiono-sulfur compounds exhibited toxic properties in mammals, including bone marrow depression, and liver damage. Pauli Virtance considered increased osteoclastic resorption in the alveolar bone surrounding the occlusal stressed tooth in conjunction with the horizontal bone loss [34]. The μCT analysis of the bone revealed that the bone structure significantly changed in TAA-treated rats. The diameter of the femur was significantly reduced, indicating that the toxic effect of the drug affected the growth of bone in rats. BMD was unaffected in cortical
bone. However, the most significant change observed in trabecular bone was the reduction of BV, TV, BS, and TS. Furthermore, a decrease in the diameter of the femur and the cortical bone thickness in the intraperitoneal TAA group was observed in Figs. 4 and 5, especially in the 400 mg/Kg TAA group compared with the control group. In the last, the force analysis of the femur represented a gradual down-trend from the normal group to the TAA-treated group. TAA administration was leading to bone fragility and increasing the risk of fracture. The μCT analysis of the bone revealed that the main part of skeletal injury caused by TAA was cortical bone, but the effect of TAA on trabecular bone was not so obvious. Therefore, our results suggest that TAA administration affects the bone metabolism of SD rats, which may relate to liver injury, but no literature suggests that acute liver injury can quickly affect bone metabolism. In this rat model, significant changes in bone metabolism were observed after only 1 month, suggesting that it may be possible to quickly build a rat model to represent bone disease for studying the mechanism of liver damage.

The liver is a multifunctional organ that occupies a key position in the modulation of protein, lipid, and carbohydrate metabolism, and it also plays a significant role in mineral metabolism and growth [35]. It has been documented that bone loss is a primitive bone disease in patients with the early liver disease [36]. Therefore, if TAA is injected intraperitoneally, TAA or TAA complex may damage the bones of rats. Osteoblasts affected osteoclast formation, differentiation, and apoptosis through several pathways, such as OPG/RANKL/RANK, RANKL/LGR4/RANK, Ephrin2/ephB4, and Fas/Fasl pathways [37]. Moschen AR demonstrated that the OPG/RANKL pathway is altered in patients with chronic liver disease, which regulates bone loss [12, 13]. In addition, rats with TAA-induced or carbon tetrachloride-induced cirrhosis showed a reduced bone volume and was histologically similar to human osteoporosis. Atsushi Nakano
suggested that chronic parenchymal liver injury causes osteoporosis due to low bone formation rates and high resorption rates. The principal pathogenesis of HOD seems to be intestinal Ca malabsorption due to lower serum albumin and villous atrophy and serum levels of vitamin D metabolites have little influence on the pathogenesis of HOD [38]. However, in healthy postmenopausal women, vitamin D supplementation significantly improved hip bone density but did not significantly reduce hip fracture, while increasing the risk of kidney stones [14]. Although vitamin D had a key role in liver injury, its relationship with TAA-induced liver injury and bone disease required further research to clarify the potential link. Osteoporosis was associated with primary biliary cirrhosis (PBC), and was a risk factor for vertebral fracture [39]. It is necessary to further explore the relationship between TAA, PBC and vertebral fractures to determine their role in the pathogenesis of liver injury.

Conclusions
Our experiment data suggest that TAA can damage the liver and even cause cancer as a widely used drug. It can also damage other organs, and when we choose a certain dose for intraperitoneal injection, it can also cause bone damage, which may pass through the liver bone axis. According to our experimental data, we suggest that TAA can cause severe damage to the weight-bearing bone of rats, especially the cortical bone and trabecular bone. The high dose of TAA caused the cortical bone to be significantly thinner; the ability to withstand huge external forces was significantly reduced, and the internal structure of the trabecular bone was seriously affected. In the end, we will continue to explore more in-depth pathological mechanisms between TAA, liver, and bone, and build a stable animal model to research TAA-caused bone disease.

Acknowledgments
Not applicable.

Authors’ contributions
JX and YL conceived and designed research. XLJ, YL, JHL, YTY and LYC conducted experiments. HS, BLW and JR contributed new reagents or analytical tools. HY and JX analyzed data. XLJ and YL wrote the manuscript. All authors read and approved the manuscript.

Funding
This work was supported by the Natural Science Foundation of Zhejiang Province (no. LY19H060001), Zhejiang Province Project of the Science and Technology Department (no. 2015C37113), Zhejiang Traditional Chinese Medicine Science and Technology Plan Project (no. 2022B093).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All experiments in this study were conducted in accordance with the animal experiment guidelines of Zhejiang Chinese Medical University Laboratory Animal Research Center (Approval No: IACUC-20181029-11; Number of Animal Use Permit: SYXK (J) 2018–0012).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 School of medical technology and information engineering, Zhejiang Chinese Medical University, Hangzhou 310053, China. 2 FUDAN University, school of basic medical sciences, Shanghai 200433, PR China. 3 Department of The Third Orthopaedic, The First Affiliated Hospital of Shihzei University School of Medicine Xinjiang Shihezi, Shihezi 832008, China.

Received: 3 July 2020  Accepted: 25 April 2022
Published online: 07 May 2022

References
1. National Toxicology Program. Thioacetamide. Rep Carcinog. 2002;10:230–1.
2. Fitzhugh OG, Nelson AA. Liver Tumors in Rats Fed Thiourea or Thioacetamide. Science. 1948;108(2814):626–8.
3. Neal RA, Halpert J. Toxicology of thiono-sulfur compounds. Annu Rev Pharmacol Toxicol. 1982;22:221–39.
4. Chilakapati J, Shankar K, Korrapati MC, Hill RA, Mehendale HM. Saturation toxicokinetics of thioacetamide: role in initiation of liver injury. Drug Metab Dispos. 2005;33(12):1877–85.
5. Pallottini V, Martin C, Bassi AM, Romano P, Nanni G, Trentalance A, et al. Rat HMGCoA reductase activation in thioacetamide-induced liver injury is related to an increased reactive oxygen species content. J Hepatol. 2006;44(4):366–74.
6. Karantonis HC, Gribblas G, Stamoulis I, Giaginis C, Seliopoulos V, Kouraklis G, et al. Platelet-activating factor involvement in thioacetamide-induced experimental liver fibrosis and cirrhosis. Dis Dig Sci. 2010;55(2):276–84.
7. Shao CH, Shen SL, Dong TF, Chai H, Yu Y, Deng L, et al. Transplantation of bone marrow-derived mesenchymal stem cells after regional hepatic irradiation ameliorates thioacetamide-induced liver fibrosis in rats. J Surg Res. 2014;186(1):408–16.
8. Patel SJ, Milwed JD, King KR, Bohr S, Iachetta-Velleu A, Li M, et al. Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol. 2012;30(2):179–83.
9. Dveep H, Monikawa Y, Gong B, Yan J, Liu Z, Chen T, et al. Mechanistic roles of microRNAs in hepatocarcinogenesis: A study of thioacetamide with multiple doses and time-points of rats. Sci Rep. 2017;7(1):3054.
10. Compston JE. Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease. Gut. 1986;27(9):1073–90.
11. Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology. 2001;33(1):301–7.
12. Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühlechner P, et al. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol. 2005;43(6):973–83.
13. Oriois LG, Pinheiro MM, Castro CH, Silva AE, Szejnfeld VL. Bone mineral density measurements, bone markers and serum vitamin D concentrations in men with chronic non-cirrhotic untreated hepatitis C. PLoS One. 2013;8(11):81652.
14. Jackson RD, LaCroix AZ, Gazz M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):686–93.
15. Iwamoto J, Seto K, Sato Y, Matsumoto H, Takeda T, Yeh JK. Effect of vitamin K2 on cortical and cancellous bone mass and hepatic lipids in rats with combined methionine-choline deficiency. Bone. 2011;48(5):1015–21.
16. Lassila V, Virtanen P. Influence of experimental liver injury on rat blood and alveolar bone under stress. Acta Anat. 1984;118(2):116–21.
17. Mirkova ET. Activities of the rodent carcinogens thioacetamide and acetamide in the mouse bone marrow micronucleus assay. Mutat Res. 1996;352(1–2):23–30.
18. Li Y, Chen M, Zhao Y, Li M, Qin Y, Cheng S, et al. Advance in drug delivery for ageing skeletal muscle. Front Pharmacol. 2020;11:1016.
19. Gupta DN. Production of cancer of the bile ducts with thioacetamide. Nature. 1955;175(4449):257.
20. Kleinfield RG. Early changes in rat liver and kidney cells induced by thioacetamide. Cancer Res. 1957;17(10):954–62.
21. Sasan T, Hilgier W, Urbanska EM, Turski WA, Albrecht J. Kynurenine acid synthesis in cerebral cortical slices of rats with progressing symptoms of thioacetamide-induced hepatic encephalopathy. J Neurosci Res. 2004;75(3):436–40.
22. Al-Bader A, Mathew TC, Khoursheed M, Asfar S, al-Sayer H, Dashti HM. Thioacetamide toxicity and the spleen: histological and biochemical analysis. Anat Histol Embryol. 2000;29(1):3–8.
23. Waters NJ, Waterfield CJ, Farrant RD, Holmes E, Nicholson JK. Metabolic approaches. Front Pharmacol. 2017;8:791.
24. Okuyama H, Nakamura H, Shimahara Y, Uyama N, Kwon YW, Kawada N, et al. Overexpression of thioredoxin prevents thioacetamide-induced hepatic fibrosis in mice. J Hepatol. 2005;42(1):117–23.
25. Nizio F, Takeyama N, Tanaka T. Changes of hepatic fatty acid metabolism produced by chronic thioacetamide administration in rats. Hepatology. 1992;15(6):1099–106.
26. Fontana L, Moreira E, Torres MI, Fernández MI, Ríos A, Sánchez de Medina F, et al. Serum amino acid changes in rats with thioacetamide-induced liver cirrhosis. Toxicology. 1996;106(1–3):197–206.
27. Al-Hashem F, Al-Humayed S, Amin SN, Kamar SS, Mansy SS, Hassan S, et al. Metformin inhibits mTOR-HIF-1α axis and profibrogenic and inflammatory biomarkers in thioacetamide-induced hepatic tissue alterations. J Cell Physiol. 2019;234(6):9328–37.
28. Jeong ES, Kim G, Shin HJ, Park SM, Oh JH, Kim YB, et al. Increased serum bile acid concentration following low-dose chronic administration of thioacetamide in rats, as evidenced by metabolomic analysis. Toxicol Appl Pharmacol. 2015;288(2):213–22.
29. Li YX, Gong XH, Liu MC, Peng C, Li P, Wang YT. Investigation of Liver Injury of Polygonum multiflorum Thunb. in Rats by Metabolomics and Traditional Approaches. Front Pharmacol. 2017;8:791.
30. Deiz-Fernandez SN, Cascales M. Intracellular calcium concentration impairment in hepatocytes from thioacetamide-treated rats. Implications for the activity of Ca (2+)-dependent enzymes. J Hepatol. 1996;24(4):460–7.
31. Takeda E, Yamamoto H, Yamanaka-Okumura H, Taketani Y. Dietary phosphorus in bone health and quality of life. Nutr Rev. 2012;70(6):311–19.
32. Burke MD. Hepatic function testing. Postgrad Med. 1978;64(3):177–82.
33. Tuñón MJ, Alvarez M, Culebras JM, González-Gallego J. An overview of vitamin K2 on cortical and cancellous bone mass and hepatic lipids in rats with combined methionine-choline deficiency. Bone. 2011;48(5):1015–21.
34. Nussler AK, Wildemann B, Freude T, Litzka C, Soldo P, Friess H, et al. Chronic CCl4 intoxication causes liver and bone damage similar to the human pathology of hepatic osteodystrophy: a mouse model to analyse the liver-bone axis. Arch Toxicol. 2014;88(4):997–1006.
35. Iwamoto J, Seki A, Sato Y, Matsumoto H, Takeda T, Yeh JK. Effect of vitamin K2 on cortical and cancellous bone mass and hepatic lipids in rats with combined methionine-choline deficiency. Bone. 2011;48(5):1015–21.
36. Nussler AK, Wildemann B, Freude T, Litzka C, Soldo P, Friess H, et al. Chronic CCl4 intoxication causes liver and bone damage similar to the human pathology of hepatic osteodystrophy: a mouse model to analyse the liver-bone axis. Arch Toxicol. 2014;88(4):997–1006.
37. Chen X, Wang Z, Duan N, Zhu G, Schwarz EM, Xie C. Osteoblast-osteoclast interactions. Connect Tissue Res. 2018;59(2):99–107.
38. Nakano A, Kanda T, Abe H. Bone changes and mineral metabolism disorders in rats with experimental liver cirrhosis. J Gastroenterol Hepatol. 1996;11(12):1143–54.
39. Guanabens N, Cerda O, Monegal A, Pons F, Caballería L, Peris P, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology. 2010;138(7):2348–56.